ArticleCurrent oncology (Toronto, Ont.)2022

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.

Alejandro Avilés-Salas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.